P1085 (DAIDS ID 10826): Duration of Human Papilloma Virus (HPV) Type-Specific Antibody After Administration of Quadrivalent HPV Vaccine to HIV-infected Children

Study Status Study Restriction


United States

What is P1085?

P1085 is a follow up study of participants enrolled in P1047 to determine the long term immunogenicity of quadrivalent HPV (QHPV) vaccine in HIV-1 infected children.  The study is designed to determine the HPV-type specific antibody levels at 2, 3.5, and 5 years after completion of the QHPV vaccine schedule and compare these to published levels of QHPV-induced antibody levels of HIV uninfected children.

Study Documents:

Sites where the study is implemented:

CRS ID Site Name City Country


Rush University Cook County Hospital Chicago NICHD CRS


United States of America

Study contacts:

CTS: Kat Calabrese


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.